Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...

Biogen Inc.: Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period ...
Le Lézard

Update on FDA Priority Review of LEQEMBI® IQLIKtm (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the review ...
Pulmonology Advisor

MMWR Highlights: US Averages 7 Large Tuberculosis Outbreaks Annually

Large tuberculosis outbreaks between 2017 and 2023 occurred at an average of 7 per year, often involving family and social networks.